Figure 3. Reduction of the manufacturing time improved CAR-T-cell function in vitro and in vivo. (A) The general procedure for manufacturing InstanCART and TraditionCART; (B) Flux (p/s) values of tumor burden assessed by IVIS imaging; (C) CAR⁺ T-cell counts of CAR-T cells in the PB of mice at different time points after CAR-T treatment. LD indicated 2×10⁶ CAR⁺ T cells in the TraditionCART group and 2×10⁶ total T cells in the InstanCART group. HD indicated 5×10⁶ CAR⁺ T cells in the TraditionCART group and 5×10⁶ total T cells in the InstanCART group. *p<0.05, **p<0.01, not significant by unpaired Mann-Whitney test. CAR-T-cell, Chimeric antigen receptor T cell; CM, cryopreservation medium; InstanCART, instant manufacturing platform; PB, peripheral blood; TraditionCART, traditional manufacturing process.